Shire, 2 generics-makers settle litigation tied to Intuniv

04/26/2013 | Reuters

Shire settled all litigation with Watson Pharma and Actavis regarding its attention-deficit/hyperactivity disorder treatment Intuniv. Under the settlement, Actavis can produce and market its generic copy of the drug in the U.S. starting Dec. 1, 2014, while Watson could follow with its version 181 days after the release of Actavis' version.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT